Next Generation Bispecifics in Solid Tumors
Nov 02, 2020•32 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this podcast, you will hear a panel discussion moderated by Dr Priti Hegde, Foundation Medicine, from the 2020 IO360° Summit regarding next generation bispecifics in solid tumors. Discussion questions include: What is happening in hematology bispecific programs compared to solid tumor bispecific programs?What do bispecifics look like in solid tumors and what is driving efficacy?What’s hindering efficacy in solid tumors compared to hematology?How can we improve on it?What should we be doing on the next generation bispecifics? Panelists: Julie Bailis, PhD, Amgen Dimitris Skokos, PhD, Regeneron Pharmaceuticals David Schaer, PhD, Pfizer Pablo Umaña, PhD, Roche To learn more about the 2021 IO360° Summit, please visit www.io360summit.com
For the best experience, listen in Metacast app for iOS or Android